Non-CYP metabolism. However, side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Oxaliplatin is an organoplatinum complex, consisting of a platinum atom complexed with 1,2-diaminocyclohexane (DACH) and a labile oxalate ligand.

Oxaliplatin is a platinum-containing antineoplastic agent used as adjuvant treatment in advanced colon cancer and as part of combination therapy in the treatment of advanced cancer of the colon and rectum. It is administered as an intravenous infusion. Common adverse reactions of oxaliplatin that can be confused with an acute porphyric attack are vomiting, nausea, obstipation, abdominal pain, back pain, peripheral sensoric neuropathy, depression and insomnia. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation; no evidence of CYP-mediated metabolism in vitro. Eliminated principally by renal excretion. Interactions with CYP metabolism of other drugs not observed. Not listed as CYP-inducer or inhibitor (Rendic, 2002).

Uneventful use reported in 1 patient with acute porphyria.